UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Safer Conception Intervention for HIV-1 Serodiscordant Couples

Completed

Conditions: HIV Seropositivity
Pregnancy, High-Risk

Interventions: Drug: PrEP
Behavioral: Counseling on timed condomless sex, ART and PrEP adherence

First Posted Date: 2017-01-25

Last Posted Date: 2018-09-12

Lead Sponsor: University of Washington

Target Recruit Count: 74

Registration Number: NCT03030768

Locations: 🇰🇪
Partners in Health, Research and Development, Thika, Kenya
🇺🇸
University of Washington, Coordinating Center, Seattle, Washington, United States

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Recurrent Ovarian Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2017-01-24

Last Posted Date: 2022-07-26

Lead Sponsor: University of Washington

Target Recruit Count: 29

Registration Number: NCT03029598

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

Phase 2

Terminated

Conditions: Stage III Fallopian Tube Cancer
Stage III Ovarian Cancer
Stage III Primary Peritoneal Cancer
Stage IIIA Fallopian Tube Cancer
Stage IIIA Ovarian Cancer
Stage IIIA Primary Peritoneal Cancer
Stage IIIB Fallopian Tube Cancer
Stage IIIB Ovarian Cancer
Stage IIIB Primary Peritoneal Cancer
Stage IIIC Fallopian Tube Cancer

Interventions: Drug: Carboplatin
Procedure: Gynecological Surgical Procedure
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Biological: pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine

First Posted Date: 2017-01-24

Last Posted Date: 2022-01-14

Lead Sponsor: University of Washington

Target Recruit Count: 11

Registration Number: NCT03029611

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

eKISS: Electronic KIOSK Intervention for Safer-Sex

Not Applicable

Completed

Conditions: Reproductive Behavior
Contraception
Sexually Transmitted Diseases

First Posted Date: 2017-01-23

Last Posted Date: 2017-01-24

Lead Sponsor: University of Washington

Target Recruit Count: 272

Registration Number: NCT03027531

Washington Study of AxoTrack-Guided Central Venous Cannulation

Not Applicable

Withdrawn

Conditions: Hypotension

Interventions: Device: AxoTrack System

First Posted Date: 2017-01-23

Last Posted Date: 2022-10-28

Lead Sponsor: University of Washington

Registration Number: NCT03027323

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Dasatinib
Drug: Doxorubicin
Drug: Etoposide
Drug: Imatinib Mesylate
Other: Laboratory Biomarker Analysis
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2017-01-18

Last Posted Date: 2022-07-13

Lead Sponsor: University of Washington

Target Recruit Count: 54

Registration Number: NCT03023046

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Effects of Leader Sleep Improvement on Leadership

Not Applicable

Conditions: Chronic Insomnia
Insomnia, Primary

Interventions: Other: Online Cognitive Behavioral Therapy for Insomnia (CBT-I)

First Posted Date: 2017-01-09

Last Posted Date: 2017-10-26

Lead Sponsor: University of Washington

Target Recruit Count: 400

Registration Number: NCT03014960

Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)

Phase 3

Active, not recruiting

Conditions: Helminthiasis
Filariasis

Interventions: Drug: Albendazole

First Posted Date: 2017-01-09

Last Posted Date: 2024-02-07

Lead Sponsor: University of Washington

Target Recruit Count: 502363

Registration Number: NCT03014167

Locations: 🇧🇯
Institut de Recherche pour le Développement, Comé, Benin
🇲🇼
London School of Hygiene and Tropical Medicine, Mangochi, Malawi
🇮🇳
Christian Medical College, Vellore, India

Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy

Not Applicable

Completed

Conditions: Hiv

Interventions: Drug: Truvada

First Posted Date: 2017-01-06

Last Posted Date: 2020-02-07

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT03012607

Locations: 🇹🇭
Sanpatong Hospital, Chiang Mai, Thailand

Spontaneous Fetal EEG Recording During Labor

Completed

Conditions: Pregnancy Abnormal

First Posted Date: 2017-01-06

Last Posted Date: 2024-01-18

Lead Sponsor: University of Washington

Target Recruit Count: 11

Registration Number: NCT03013569

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy